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Abstract
Anti-EGFR therapy is commonly used to treat colorectal cancer (CRC), although only a subset of patients benefit from the
treatment. While KRAS mutation predicts non-responsiveness, positive predictive markers are not in clinical practice. We
previously showed that immunohistochemistry (IHC)-guided EGFR gene copy number (GCN) analysis may identify CRC
patients benefiting from anti-EGFR treatment. Here we tested the predictive value of such analysis in chemorefractory
metastatic CRC, elucidated EGFR GCN heterogeneity within the tumors, and evaluated the association between EGFR GCN,
KRAS status, and anti-EGFR antibody response in CRC cell lines. The chemorefractory patient cohort consisted of 54 KRAS
wild-type (WT) metastatic CRC patients. EGFR GCN status was analyzed by silver in situ hybridization using a cut-off value of
4.0 EGFR gene copies/cell. KRAS-WT and KRAS mutant CRC cell lines with different EGFR GCN were used in in vitro studies.
The chemorefractory CRC tumors with EGFR GCN increase ($4.0) responded better to anti-EGFR therapy than EGFR GCN (,
4.0) tumors (clinical benefit, P= 0.0004; PFS, HR = 0.23, 95% CI 0.12–0.46). EGFR GCN counted using EGFR IHC guidance was
significantly higher than the value from randomly selected areas verifying intratumoral EGFR GCN heterogeneity. In CRC cell
lines, EGFR GCN correlated with EGFR expression. Best anti-EGFR response was seen with KRAS-WT, EGFR GCN = 4 cells and
poorest response with KRAS-WT, EGFR GCN = 2 cells. Anti-EGFR response was associated with AKT and ERK1/2
phosphorylation, which was effectively inhibited only in cells with KRAS-WT and increased EGFR GCN. In conclusion, IHC-
guided EGFR GCN is a promising predictor of anti-EGFR treatment efficacy in chemorefractory CRC.
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Introduction
Epidermal growth factor receptor (EGFR) signaling is com-
monly activated in colorectal cancer (CRC). EGFR-targeting
monoclonal antibodies (mAb) have become a standard treatment
option, particularly in the chemorefractory phase of metastatic
disease [1]. KRAS, a signaling molecule downstream of EGFR, is
mutated in approximately 40% of CRCs [1] and these activating
mutations convey anti-EGFR treatment resistance [2]. In KRAS
wild-type (WT) tumors, objective response is achieved in every
third patient indicating that other factors contribute to drug
efficacy [3]. Thus, there is urgent need for novel predictive
markers.
EGFR gene copy number (GCN) increase has been linked to
anti-EGFR treatment response. Most studies have shown an
association between GCN level and clinical benefit, progression
free survival (PFS), and in some cases, with overall survival (OS)
[4–6]. However, EGFR GCN is not currently utilized in the
clinical context because of technical obstacles and considerable
variation between the scoring systems [7]. We recently reported a
novel algorithm, which may improve the predictive value of EGFR
GCN. We first showed that the EGFR GCN as analyzed by silver
in situ hybridization (SISH) positively correlated with immunohis-
tochemistry (IHC), when the evaluation was performed from
tumor areas of highest staining intensity [8]. We further
demonstrated that an increased EGFR GCN, using cut-off value
($4.0), correlated positively with response to anti-EGFR therapy
in all three parameters analyzed: clinical benefit, PFS, and OS.
EGFR GCN was independent of KRAS status, and when the two
analyses were combined, they predicted treatment response better
than either test alone. The mean EGFR GCN, as analyzed by this
method was 5.5, and copy number increase $4.0 was seen in 64%
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of the tumors. The GCN increase was typically associated with
Chromosome 7 polysomy, whereas high level amplification was
rarely seen.
A reason for the variation in published EGFR GCN results may
be tumor heterogeneity, which has not been addressed in earlier
studies. There is some evidence that EGFR may be heteroge-
neously expressed within individual colorectal tumors, both at
gene and protein level [5]. Heterogeneity may complicate the
analysis of EGFR protein expression and copy number alterations
and lead to poor test reproducibility [7,9]. This may be especially
relevant in FISH-based analysis, where the GCN counting cannot
be correlated with histology [7]. If EGFR heterogeneity plays a
biological role, then an algorithm, in which protein expression
(IHC) guides EGFR GCN evaluation, could improve the predictive
value.
The aim of this study was to test the novel EGFR GCN method
in an independent patient cohort and to assess the impact of EGFR
GCN status with outcome in a combined chemorefractory patient
cohort. In both patient cohorts an EGFR increase ($4.0) was
shown to associate with an improved clinical outcome, including
clinical benefit rate, PFS, and OS. Secondary aims were to
elucidate EGFR GCN heterogeneity within the tumors and to test,
whether CRC cell lines with various EGFR GCN, respond
differently to EGFR mAbs. According to our results, EGFR
GCN is heterogeneous in CRC and the values obtained with IHC
guidance from selected tumor areas are higher than the ones
obtained by random selection. Importantly only the EGFR GCN
counted with EGFR IHC guidance was able to predict response to
anti-EGFR treatment. Our in vitro studies support our clinical
findings, since the best response to anti-EGFR treatment was seen
in KRAS WT, EGFR GCN = 4.0 cells and poorest response in the
KRAS WT, EGFR GCN = 2 cells.
Materials and Methods
Patients
The original Turku University Hospital discovery cohort has
been reported [8]. The validation cohort consisted of 31 KRAS-
WT patients treated with EGFR mAbs in second to sixth line at
the Helsinki University Hospital for metastatic CRC between June
2008 and July 2010. The selection criteria for this study were: (I)
tissue was available from the primary tumor at diagnosis prior to
start of any treatment, (II) the tumor was KRAS-WT, (III) the
patients received second- to sixth-line treatment with cetuximab or
panitumumab with or without chemotherapy, and (IV) the
patients had no other malignancy in their history. The histology
of each validation cohort case was re-evaluated by an expert in GI-
pathology (AR).
The combined cohort of chemorefractory patients included 54
patients, 25 from the original Turku cohort and 29 from the
Helsinki validation set. The chemorefractory patient cohort
included patients treated with anti-EGFR mAbs in third line or
more, either as single therapy or in combination with irinotecan
+/2 a fluoropyrimidine. Key characteristics of all three cohorts
are described in Table 1.
The response to anti-EGFR treatment was evaluated by
computed tomography (CT) or magnetic resonance imaging
(MRI) according to the Response Evaluation Criteria in Solid
Tumors (RECIST version 1.1) [10]. Clinical benefit was
considered partial response (PR) or at least 3 months of stable
disease (SD). Progression free survival (PFS) was calculated from
the onset of anti-EGFR treatment until disease progression.
Overall survival (OS) was calculated from the onset of anti-EGFR
therapy until death of any cause.
Ethics Statement
The study was conducted in accordance with the Declaration of
Helsinki. The clinical data were retrieved and histological samples
collected and analyzed with the endorsement of the National
Authority for Medico-Legal Affairs as well as the Institutional
Review Board of the Hospital District of Southwest Finland and
Ethical Review Board at Helsinki University Hospital. Written or
oral informed consent was not obtained due to the fact that a large
portion of the patients included in this retrospective study had died
of their disease. The need for informed consent from participants
was waived by the National Authority for Medico-Legal Affairs.
IHC and SISH Procedures
KRAS mutation analysis was performed with the DxS KRAS
mutation kit (DxS Ltd, Manchester, UK). Detailed methods for
EGFR IHC and EGFR GCN have been described [8]. In brief,
three mm sections were first stained with EGFR (clone 5B7) mAb
(Ventana Medical Systems/Roche Diagnostics, Tucson AZ, USA).
Stainings were performed with BenchMark XT (Ventana/Roche)
using ultraVIEW Universal DAB Detection Kit (Ventana/Roche).
EGFR gene was detected from subsequent five mm sections with
EGFR DNA Probe (Ventana/Roche) and ultraVIEW SISH
Detection Kit (Ventana/Roche). In each tumor, EGFR GCN of
forty tumor cells was analyzed using a 40x objective by two
observers (ML, JS) from areas of highest IHC reactivity. The
investigators were blinded of the clinical information. To evaluate
the average EGFR GCN within each tumor, five tumor areas were
arbitrarily chosen. From each of these areas, EGFR GCN of 20
randomly selected cancer cells was counted by two observers (TA,
JS). The results were reported as mean and range within each
area.
Cell Lines, Western Blotting and Cytotoxicity Assays
The C2BBe1, SK-CO-1 and NCI-H747 cell lines were
purchased from ATCC (Manassas, VA, USA) and the CW-2 cell
line from RIKEN bioresource center (Tsukuba, Japan). The NCI-
H747 and CW-2 cells were cultured in RPMI-1640, the SK-CO-1
cells in EMEM and C2BBe1 cells in DMEM supplemented with
0.01 mg/ml human transferrin (Sigma, Saint Louis, MO, USA).
All media were supplemented with 10% FBS, 2 mM glutamine
and 1% penicillin/streptomycin.
For the signaling pathway analysis cells were grown on 6-well-
plates and allowed to attach for 12 hours in normal medium. Then
they were changed into medium with 1% FBS and given 0–
200 mg/ml cetuximab (Erbitux, Merck Serono) for 24 hours.
25 mg/ml EGF was given to the cells for five minutes before lysis.
Protein levels were analyzed by Western blotting of cells lysed in
RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Nonidet P-40,
0.5% deoxycholate, 0.1% SDS, 1 mM orthovanadate, and
protease inhibitor mixture, pH 7.4). Proteins were resolved by
SDS-PAGE and transferred to nitrocellulose membranes. After
overnight incubation in +4Cu with primary antibody [anti-EGFR
(D38B1, Cell Signaling Technology, Danvers, MA, USA),
phospho-EGFR (Tyr1173, 53A5, Cell Signaling Technology),
ERK2 (K-23, Santa Cruz Biotechnology, Dallas, TX, USA),
phospho- ERK1/2 (Thr202/Tyr204, D13.14.4E, Cell signaling
Technology), phospho-AKT (Ser 473), panAKT (C67E7, Cell
Signaling Technology)], the membranes were incubated for 1 hour
at room temperature with horseradish peroxidase-conjugated
secondary antibody (Dako, Glostrup, Denmark) and the signals
were detected with SuperSignal West Pico chemiluminescent
substrate (Thermo Scientific, Waltham, MA, USA). Anti-a-tubulin
mAb (B-1–5-1–2, Sigma) or HRP-conjugated anti-GAPDH mAb
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(mAbcam 9484, Abcam, Cambridge, UK) was used as a loading
control.
For cell viability assays, 5000 cells/well were plated on 96-well
plates. After overnight incubation in the presence of 2% FBS, the
cells were exposed to 0–200 mg/ml cetuximab (Erbitux, Merck
Serono) or panitumumab (Vectibix, Amgen) for 72 hours in
medium supplemented with 1% FBS. Each treatment was done in
triplicate and the experiment was repeated four times. Cell
viability was assessed with the CellTiter 96 Aqueous One Solution
Cell Proliferation assay (Promega, Madison, WI, USA). The cell
viability is given as percentage of the control cells.
Statistical Analysis
Statistical analyses were performed with the SAS 9.2 and
Enterprise Guide 4.2 programs (SAS Institute Inc., Cary, NC).
Frequency table data were analyzed with the x2-test or Fisher’s
exact test. The difference in EGFR GCN values obtained by
different evaluation methods (normally distributed variables) was
calculated with the Students t-test. Kaplan-Meier and log-rank
tests as well as Cox proportional hazards regression model were
used for univariate survival analysis. All statistical tests were two-
sided. P-values,0.05 were considered to be statistically significant.
The statistical significance for the cell viability assays was
calculated with Microsoft Excel 2011 and StatPlus:mac LE
(Version 2009, AnalystSoft Inc.). The significance between the
differences in the responses in the cell lines was determined with
two-way ANOVA followed by multiple t-tests.
Table 1. Characteristics of anti-EGFR treated KRAS wild type metastatic colorectal cancer patients.
(a) Original discovery patient cohort
( = 44)
(b) Independent validation
patient cohort (n=31)
(c) Combined chemorefractory
patient cohort (n=54)
Median age in years (range) 60 (34–73) 63 (37–81) 61 (37–81)
n (%)
Turku University Hospital 44 (100) - 25 (46.3)
Helsinki University Hospital - 31 (100) 29 (53.7)
Sex
Female 18 (40.9) 14 (45.2) 21 (38.9)
Male 26 (59.1) 17 (54.8) 33 (61.1)
Site of primary tumor
Colon 32 (72.7) 21 (67.7) 38 (70.4)
Rectum 12 (27.3) 10 (32.3) 16 (29.6)
Tumor differentiation grade
Grade 1 6 (13.6) 4 (12.9) 7 (13.0)
Grade 2 28 (63.7) 21 (67.7) 36 (66.7)
Grade 3 6 (13.6) 4 (12.9) 6 (11.1)
Unknown 4 (9.1) 2 (6.4) 5 (9.2)
Stage of disease at diagnosis
Stage I - 1 (3.2) 1 (1.8)
Stage II 9 (20.4) 2 (6.4) 9 (16.7)
Stage III 11 (25.0) 9 (29.0) 13 (24.1)
Stage IV 24 (54.6) 19 (61.3) 31 (57.4)
Anti-EGFR therapy
Cetuximab 35 (79.5) 13 (41.9) 31 (57.4)
Panitumumab 8 (18.2) 16 (51.6) 21 (38.9)
Both 1 (2.3) 2 (6.5) 2 (3.7)
Line of therapy
First 5 (11.4) - -
Second 12 (27.3) 2 (6.4) -
Third or more 27 (61.3) 29 (93.5) 54 (100)
Anti-EGFR combination therapy
Anti-EGFR combined to IRI 32 (72.7) 23 (74.2) 43 (79.6)
Anti-EGFR combined to CAP 1 (2.3) - -
Anti-EGFR combined to OXA 8 (18.2) - -
Single treatment 3 (6.8) 8 (25.8) 11 (20.4)
CAP, capecitabine; EGFR = epidermal growth factor receptor; IRI, irinotecan; OXA, oxaliplatin.
Original discovery patient cohort (a). Independent validation patient cohort (b). Combined chemorefractory patient cohort (c).
doi:10.1371/journal.pone.0099590.t001
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Results
EGFR GCN Test Validation with an Independent Patient
Cohort
To validate our earlier results on the association between EGFR
GCN and anti-EGFR treatment response, we studied an
independent patient cohort treated at the Helsinki University
Hospital. The methods for EGFR GCN detection and the cut-off
value for GCN increase were identical to the discovery study [8].
In the validation cohort, 18 out of 31 (58%) tumors had an EGFR
GCN above the cut-off value ($4.0), as compared to 64% in the
original discovery set. Fourteen (78%) of the high EGFR GCN ($
4.0) KRAS-WT patients showed clinical benefit [partial response
(PR) + stable disease (SD)] from anti-EGFR therapy, whereas only
4 (31%) of low EGFR GCN (,4.0) benefited from treatment (Chi-
square Test, P= 0.009). An elevated EGFR GCN associated
significantly with improved survival. The median PFS time of
EGFR GCN$4.0 was 25 weeks compared to only 11 weeks of the
EGFR GCN,4.0 patients (Log-Rank test, P= 0.002; Cox test,
P= 0.003, HR = 0.28, 95% CI 0.12–0.65; Figure 1a). Further-
more, the EGFR GCN$4.0 associated significantly with improved
OS (median 12.1 versus 8.2 months; Log-Rank test, P= 0.004;
Cox test, P= 0.006, HR = 0.32, 95% CI 0.14–0.72; Figure 1b).
Correlation between EGFR GCN and Treatment Response
in Chemorefractory Patients
We combined the chemorefractory KRAS WT patients from
both cohorts (n= 54) for further statistical analyses. Eighty per cent
(28 out of 35) of the patients with a high EGFR GCN ($4.0)
achieved clinical benefit. In contrast, the clinical benefit rate was
only 32% (6 out of 19) for the patients with a low EGFR GCN (,
4.0) (Chi-Square test, P= 0.0004).
We analyzed separately the 31 chemorefractory patients treated
with cetuximab (57%) and 21 with panitumumab (39%). Two
patients were treated with both anti-EGFR antibodies sequentially
and therefore excluded from the analysis. The clinical benefit rate
in the patients treated with cetuximab +/2 cytotoxic therapy with
a high EGFR GCN in their primary tumors was 86% (18/21) as
compared to 20% (2/10) in the group of patients with an EGFR
GCN,4.0 (Fishers Exact test, P= 0.0007). In the patient group
treated with panitumumab +/2 cytotoxic therapy clinical benefit
was 67% (8/12) in the patients with a high EGFR GCN and 44%
(4/9) in those with a low EGFR GCN. The results are presented
more in detail in Table S1.
Increased EGFR GCN Associates with Improved PFS and
OS in Chemorefractory Disease
The median PFS of the chemorefractory patient cohort was
significantly longer in the EGFR GCN$4.0 patients than in the
EGFR GCN,4.0 patients; 29.5 vs. 10.8 weeks (Log-Rank test, P,
0.0001; Cox test, P,0.0001, HR = 0.23, 95% CI 0.12–0.46). The
median OS time for patients with EGFR GCN$4.0 tumors was
12.5 months compared to 7.2 months for those with EGFR GCN
below the cut-off value (Log-Rank test, P= 0.0002; Cox test,
P= 0.0003, HR = 0.32, 95% CI 0.17–0.59). Kaplan-Meier
survival curves are shown in Figure 1 c–d.
PFS remained longer in the patients with a high EGFR GCN
regardless of which anti-EGFR mAb was used. In the patients
treated with cetuximab +/2 cytotoxic therapy the median OS
time was statistically significantly longer in the cohort of patients
with an EGFR GCN$4.0 as compared to those with an EGFR
GCN below 4.0 (12.5 vs. 4.6 months; Log-Rank test P= 0.0006;
Cox test P= 0.001, HR 0.25, 95% CI 0.10–0.58), whereas no
statistically significant OS difference was seen in the patients
treated with panitumumab. The results are shown in Table S1.
The survival data of the original discovery-, the independent
validation-, and combined chemorefractory patient cohorts are
compared in Figure 2.
EGFR GCN Heterogeneity within Tumors
EGFR GCN was randomly evaluated, without IHC guidance,
from all 31 validation cohort tumors. The mean EGFR GCN
values from randomly selected areas were significantly lower when
compared to the method where the EGFR GCN was evaluated
selectively from areas with highest EGFR protein expression (P,
0.0001). The median EGFR GCN of these 31 primary CRC
tumors was 4.3 when IHC guidance was used and 3.3 when the
analysis was performed in a random fashion. The heterogeneity of
EGFR GCN within one CRC tumor sample is demonstrated in
Figure 3.
When the randomly chosen EGFR GCN values were used for
survival analyses (EGFR GCN$4.0 vs. EGFR GCN,4.0) no
statistically significant difference was observed between the two
groups (PFS: P= 0.07, HR 0.40, 95% CI 0.15–1.08; OS: P= 0.22,
HR = 0.58, 95% CI 0.25–1.38). No significant difference in anti-
EGFR treatment efficacy (clinical benefit vs. progressive disease)
were noted either (Fishers Exact test, P= 0.19).
EGFR GCN and Response to Anti-EGFR Abs In vitro
We searched the Sanger Center cancer cell line database
(http://www.sanger.ac.uk/cgi-bin/genetics/CGP/cghviewer/
CghHome.cgi) for EGFR GCN alterations. A low level of EGFR
GCN increase (4–15 copies/cell), typically due to Chromosome 7
polysomy, was seen in 18 out of 39 (46%) cell lines. To correlate
the EGFR GCN and KRAS status with anti-EGFR mAb response,
we chose four lines for analysis. The CW-2 and C2BBe1 cell lines
are KRAS-WT and have two and four copies of EGFR,
respectively. NCI-H747 and SK-CO-1 are both KRAS mutant
and have more than four copies (6–7) of EGFR. The EGFR GCN
was confirmed by SISH (Figure 4a). The EGFR GCN was directly
reflected in EGFR protein expression as indicated by Western blot
analysis (Figure 4b). In cell viability assays, the KRAS-WT cell line
with EGFR GCN 4 (C2BBe1) was the most sensitive to both
cetuximab and panitumumab treatment (Figure 4c). The differ-
ence was highly significant when compared to any of the other cell
lines (Student’s t-test, P,0.001). Interestingly, the EGFR disomic,
WT KRAS cell line (CW-2) was most resistant to mAb treatment.
The cell lines with mutant KRAS and EGFR GCN.4 showed
intermediate sensitivity, especially to panitumumab treatment.
The results are thus in agreement with our clinical data indicating
that both EGFR GCN and KRAS status define the tumor cell
response to anti-EGFR mAbs.
We further looked at the effect of anti-EGFR mAb treatment on
intracellular signaling in these cell lines. In KRAS mutant cell lines
with more than four EGFR gene copies, phosphorylation of EGFR
was evident and efficiently blocked by anti-EGFR mAb (Figure 4e).
Anti-EGFR inhibition partially reduced pERK1/2 levels, while
the level of pAKT was not affected. In KRAS-WT cell lines with 2–
4 EGFR gene copies EGFR phosphorylation was under detection
limit (not shown). However, the pathway was apparently
operational as indicated by responses on downstream signaling.
In the EGFR disomic line CW-2, anti-EGFR mAb treatment
reduced pERK1/2 level, but did not affect AKT phosphorylation
(Figure 4e). Only in EGFR polysomic and wild-type KRAS C2BBe1
cells, an effective blockage of both ERK1/2 and AKT signaling,
was detected (Figure 4e). These results thereby suggest that both
EGFR GCN and KRAS mutation status determine the effect of
EGFR Gene Copy Number and Anti-EGFR Response in Colorectal Cancer
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anti-EGFR mAb on EGFR downstream signaling and colorectal
cancer cell survival.
Discussion
In this study, we demonstrate that heterogeneous EGFR GCN
increase is a strong predictor of anti-EGFR treatment benefit in
metastatic CRC. The results extend our previous findings of a
single institute patient cohort to an independent validation cohort.
In addition, they demonstrate the predictive value of EGFR GCN
for anti-EGFR therapy efficacy in chemorefractory CRC patients,
the most important patient group eligible for this treatment. The
results further show that intra-tumoral EGFR GCN heterogeneity
is common in CRC. We hypothesize that this previously
unaccounted EGFR heterogeneity is a reason for the reported
poor correlation between EGFR GCN analysis and efficacy of anti-
EGFR therapy, and suggest an improved method for predictive
EGFR GCN testing.
The patient material in our study included patients treated with
anti-EGFR therapy both in an early and chemorefractory phase of
metastatic CRC therapy. To control for the confounding effects of
chemotherapy sensitivity when combined with anti-EGFR mAbs
on our results, the predictive value of EGFR GCN on anti-EGFR
treatment response was evaluated separately in the subgroup of
patients treated in a chemorefractory phase (third line or more).
The results obtained in the chemorefractory subgroup were similar
to the results of the entire patient cohort, which supports our
interpretation that a high EGFR GCN is indeed a predictor of
favorable anti-EGFR treatment response.
Both cetuximab and panitumumab in the chemorefractory
patient subgroup demonstrated improved PFS in EGFR GCN$
4.0 patients. Overall survival and disease control rate was
statistically improved for the cetuximab cohort, and numerically
but not statistically in the small panitumumab cohort. The two
therapeutic Abs are of different type, panitumumab being a fully
human mAb, whereas cetuximab is a mouse-human chimera. In
vitro assay demonstrated identical cytotoxicity for the tested CRC
lines, but in vivo, other mechanisms, including antibody-dependent
cytotoxicity (ADCC) may be operational. In this respect,
cetuximab and panitumumab may be different and therefore,
increased EGFR GCN could better indicate sensitivity to
Figure 1. Kaplan Meier survival curves of KRAS wt colorectal cancer patients treated with anti-EGFR therapy. Progression free survival
(a) and overall survival (b) of the test validation cohort according to EGFR gene copy number. Progression free survival (c) and overall survival (d) of
the combined chemorefractory patient cohort.
doi:10.1371/journal.pone.0099590.g001
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cetuximab treatment [11]. According to pre-clinical and clinical
data certain cytotoxic therapies +/2 immunomodulating agents,
including e.g. the GILF (gemcitabine, irinotecan, levofolinic, and
5-fluorouracil), GILFI (gemcitabine, irinotecan, levofolinic acid,
fluorouracil, aldesleukin), and GOLFIG (gemcitabine, oxaliplatin,
levofolinate, 5-fluorouracil, GM-CSF, aldesleukin) regimens, have
the ability to effectively up-regulate EGFR expression on colon
cancer cells, thereby enhancing the sensitivity of the colon cancer
cells to cetuximab-mediated ADCC [12–14]. In our study,
panitumumab was used as single therapy more often than
Figure 2. Progression-free survival and overall survival of anti-EGFR treated patients according to EGFR gene copy number. The
hazard ratios and confidence intervals of the original discovery, validation, and combined chemorefractory patient cohorts are shown. A high EGFR
GCN (IHC guided SISH) is associated with an improved disease outcome in all three KRAS wild type metastatic colorectal cancer patient cohorts
treated with anti-EGFR therapy (two independent cohorts and one combined cohort of chemorefractory patients).
doi:10.1371/journal.pone.0099590.g002
Figure 3. EGFR immunohistochemistry and EGFR silver in situ hybridization analysis in colorectal cancer. EGFR IHC shows
heterogeneous staining with intensive membranous reactivity in the middle (a). EGFR SISH from the intensively stained area showing gene clusters
(b). EGFR SISH from the surrounding areas with weak or negative EGFR IHC staining shows marginally elevated or normal gene copy numbers (c–d).
doi:10.1371/journal.pone.0099590.g003
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Figure 4. Anti-EGFR response of colorectal cancer lines with different EGFR GCN and KRAS status. (a) EGFR GCN SISH analysis of the
different cell lines. (b) A western blot image showing the levels of EGFR protein in the different cell lines. a-tubulin was used as a control for equal
loading. The cell viability of the different cell lines at varying concentrations of (c) cetuximab and (d) panitumumab. The results are given as
percentage of viable cells in comparison to the non-treated cells (mean6 SE of five experiments). (e) Western blots showing EGFR pathway signaling
molecules in the different cell lines. The cells were pretreated with the indicated amounts of cetuximab for 24 hours in medium containing 1% FBS
and given egf (25 mg/ml) for 5 minutes before lysis. The indicated signaling molecules were analyzed with western blotting. GAPDH was used as a
control for equal loading.
doi:10.1371/journal.pone.0099590.g004
EGFR Gene Copy Number and Anti-EGFR Response in Colorectal Cancer
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cetuximab, 42.9 vs 6.5% respectively, which at least in part can
explain the difference observed in the efficacy results between the
two antibodies. Both antibodies, when not administered as single
treatment, were combined with irinotecan based chemotherapy
regimens. In our study, oxaliplatin or single capecitabine were not
combined to anti-EGFR therapy in the chemorefractory phase of
the disease. Two patients were given cetuximab and panitumumab
sequentially and therefore excluded from this study. Therefore,
neither the combination cytotoxic drug nor the administration of
both antibodies sequentially, explains the difference in the results
obtained with the different anti-EGFR antibodies. Alternatively,
our result may reflect a difference between treated patients.
Cetuximab was more commonly used in the discovery cohort,
which defined the test cut-off value, and panitumumab in the
validation cohort with only chemorefractory patients. As both
cohorts were retrospective, we cannot exclude differences in the
patient populations, which could account for the differences in
treatment results.
Tumor heterogeneity has been suggested to contribute to
difficulties encountered in the validation of oncology biomarkers
[15]. In the present work, the mean EGFR GCN values were
significantly lower when analyzed in a random fashion as
compared to the values obtained by choosing the cells with the
highest GCN. Only the latter method was able to distinguish
patients according to their anti-EGFR treatment response. This
supports the view that therapeutic decision making based on
scoring the dominant phenotype may be misleading [15]. Even a
minor percentage of mutant alleles and gene expression profiles
can be crucial for treatment response [16].
EGFR GCN heterogeneity is a well-established phenomenon in
gliomas [17]. Although EGFR GCN heterogeneity in CRC may
have been identified earlier, this finding has been generally
disregarded, and not utilized as a parameter in diagnostic analyses.
In some respects, the association between EGFR GCN and
treatment response resembles the findings of another EGFR family
member, Her2, in gastric cancer. Her2 is amplified or overex-
pressed in 7–34% of gastric cancers [18]. Unlike in breast cancer,
Her2 expression in gastric cancer shows marked intra-tumoral
heterogeneity, and therefore diagnostic test interpretation differs
from breast cancer [19]. The current predictive diagnostics for
trastuzumab treatment in gastric cancer is based on a combination
of Her2 IHC and Her2 GCN analysis of areas with highest IHC
staining. In biopsies, such areas may cover just 5% of the tumor
[19]. Although there are parallels, the Her2-gastric cancer
algorithm differs from EGFR GCN in CRC. In gastric cancer,
the cut-off value is based on gene to chromosome ratio $2.0,
although most recent recommendations suggest that Her2 GCN.
6.0 can be considered as positive. In CRC, the EGFR GCN
increase is typically a result of chromosome 7 polysomy and
therefore the gene to chromosome ratio is not informative. On the
other hand chromosome 17 is rarely polyploid in gastric cancer,
which indicates a different biological mechanism for EGFR and
Her2 increase.
Tumor heterogeneity has been suggested to underlie resistance
to targeted cancer therapeutics [15]. In this respect, the finding
that a minor population of EGFR GCN high cells defines
treatment response is unexpected. As the EGFR GCN low cells
do not respond to treatment (the EGFR GCN low tumors are
unresponsive), the most obvious outcome would be treatment
failure, when the EGFR GCN low cells take over. This appears,
however, not to be the case, therefore alternative explanations
must be considered. One possibility is that the EGFR GCN high
cells possess biological activities that determine the outcome of the
entire tumor cell population. In such case, EGFR high cells may
have yet undefined properties, such as paracrine effects on the
major tumor cell population or features of cancer stem cells. There
is evidence that, indeed, the transcriptome of the EGFR GCN high
cells differs from EGFR low cells and that the EGFR pathway is
associated with intestine stem cell properties [20,21]. At present,
the mechanism by which EGFR GCN high cells dictate treatment
response remains unknown.
EGFR signaling results in activation of intracellular pathways
such as Ras/Raf/MAPK/ERK and PI3K/AKT, which regulate
cell proliferation and survival. Anti-EGFR mAb:s are suggested to
exert their anti-cancer effects by blocking these pathways [22].
Our cell line studies suggested a mechanism, by which the
combination of EGFR GCN and KRAS mutation status can
regulate the response to anti-EGFR treatment. EGFR inhibition
with mAbs led to suppression of AKT pathway activity only in
cells with increased EGFR GCN and KRAS-WT. Although EGFR
phosphorylation was effectively blocked in KRAS mutant cells,
AKT signaling was not suppressed, apparently due to constitu-
tively active KRAS. Interestingly, in EGFR disomic and KRAS-WT
cells, AKT signaling was active but not responding to anti-EGFR
mAb suggesting that cells with normal EGFR GCN utilize
alternative mechanisms to sustain AKT signaling. Similarly, the
ERK1/2 phosphorylation was fully supressed only in cells with
increased EGFR GCN and WT KRAS. In conclusion, this study
indicates that the diagnostic algorithm combining EGFR IHC and
EGFR SISH is a highly promising method for selecting CRC
patients benefiting from anti-EGFR treatment. When combined
with KRAS mutation testing, the ratio of responsive patients in the
test positive group may almost double as compared to KRAS test
alone. If further test validation using prospectively collected and
randomized patient cohorts confirms the test results, these findings
may have a profound effect on future selection of CRC patients for
anti-EGFR therapy.
Supporting Information
Table S1 Tumor response and survival of patients with
chemorefractory KRAS wild type metastatic or locally advanced
colorectal cancer treated with cetuximab or panitumumab
according to EGFR Gene Copy Number.
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